AstraZeneca Leads Bid for Abivax as Eli Lilly Waits in the Wings
AstraZeneca gains exclusive data access to acquire surging French biotech Abivax (up 1,600% in 2025) before March 23 deadline; Eli Lilly waits in wings amid IBD drug promise.
/ 894 items
#Healthcare↓
Solid Biosciences Reports Strong Interim Results for SGT-003 Gene Therapy in Duchenne Trial
Solid Biosciences’ gene therapy SGT-003 shows early promise for Duchenne; trial patients improved muscle and heart function, with potential accelerated FDA approval in 2026.
Wells Fargo gives Atrium Therapeutics a Strong Buy rating on its rare cardiomyopathy programs
Wells Fargo analyst initiates coverage on Atrium Therapeutics with Overweight rating and $25 price target, highlighting big potential in RNA therapies for rare genetic heart diseases with no current treatments.
Kala Bio Stock Surges as First Biotech AI Agent Launches in Just 14 Days
Kala Bio shares surged 63% premarket to 48 cents after announcing the launch of its first purpose-built AI agent for biotech in just 14 days through the rebranded Researgency.ai platform.
Ocugen Gets Wall Street Boost: Oppenheimer Initiates Outperform Coverage with $10 Price Target
Oppenheimer starts coverage on Ocugen with an Outperform rating and $10 price target, highlighting its lead gene therapy OCU400 in Phase 3 for retinitis pigmentosa and big market potential by 2027.
C-Further Selects MiNK’s iNKT Platform for First Pediatric Oncology Partnership
MiNK Therapeutics announces a new collaboration with C-Further to advance PRAME-targeted iNKT cell therapy for pediatric cancers, including up to $1.1 million in funding.